此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

体外冲击波疗法与富血小板血浆治疗中段跟腱病

2026年9月23日 更新者:Adam Tenforde、Spaulding Rehabilitation Hospital

一项评估物理疗法、冲击波疗法、富血小板血浆或联合治疗对中段跟腱病管理影响的随机对照试验

Midportion Achilles tendinopathy is a common cause of pain and functional limitation in both athletes and the general population. Progressive tendon loading programs are considered first-line treatment but do not lead to satisfactory outcomes in all patients. Extracorporeal shockwave therapy (ESWT) and platelet-rich plasma (PRP) injections are commonly used interventions for refractory symptoms, yet evidence supporting their combined use is limited particularly in treating Achilles tendon disorders.

This randomized controlled trial will evaluate the effectiveness of a standardized exercise program alone or in combination with PRP injection, ESWT, or both therapies in active adults with midportion Achilles tendinopathy. Participants will be randomized to one of four treatment groups and followed for six months. The primary outcome will assess changes in Achilles tendon symptoms and function using the Victorian Institute of Sport Assessment-Achilles (VISA-A) score. Secondary outcomes will include patient-reported outcomes, physical function testing, ultrasound tendon structure measures, and gait biomechanics.

研究概览

详细说明

Midportion Achilles tendinopathy (Mid-AT) is characterized by pain, stiffness, and impaired function resulting from a failed tendon healing response. Progressive loading exercise programs such as the Silbernagel protocol represent the current standard treatment and provide meaningful improvement for many individuals. However, approximately 40% of patients continue to experience persistent symptoms despite rehabilitation.

Extracorporeal shockwave therapy (ESWT) and platelet-rich plasma (PRP) injections are increasingly used in clinical practice to address refractory symptoms. ESWT is proposed to stimulate tissue healing through mechanotransduction and has demonstrated improved outcomes when combined with exercise therapy in some studies. PRP contains concentrated autologous growth factors that may enhance tendon healing through stimulation of extracellular matrix production, angiogenesis, and collagen synthesis.

Despite increasing clinical use, there remains limited evidence evaluating the comparative or combined effects of PRP and ESWT in the treatment of Achilles tendinopathy. Furthermore, few trials have evaluated these therapies within a standardized rehabilitation framework.

The purpose of this randomized controlled trial is to evaluate the effectiveness of exercise therapy alone compared with exercise therapy combined with PRP injection, ESWT, or both interventions in individuals with chronic midportion Achilles tendinopathy. Participants will be randomized to one of four treatment groups: exercise with sham procedures (control), exercise plus PRP injection, exercise plus ESWT, or exercise combined with PRP and ESWT. Participants will be followed for six months to evaluate patient-reported outcomes, tendon structure using ultrasound, physical function testing, and gait biomechanics. This study aims to determine whether PRP, ESWT, or the combination of both treatments provide superior functional recovery compared with exercise-based rehabilitation alone.

研究类型

介入性

注册 (估计的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Massachusetts
      • Cambridge、Massachusetts、美国、02138
        • Spaulding Cambridge Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 18-65 years
  • Diagnosis of unilateral midportion Achilles tendinopathy
  • Symptoms present for more than 3 months
  • VISA-A score <80 at baseline
  • Pre-injury physical activity level ≥3 on the Physical Activity Scale
  • Ability to participate in rehabilitation program

Exclusion Criteria:

  • Symptoms present for less than 3 months
  • Prior PRP injection or ESWT treatment to the Achilles tendon within 3 months
  • Other lower extremity musculoskeletal injury affecting function
  • Symptomatic arthritis affecting the ankle or foot
  • Rheumatologic disease or connective tissue disorder
  • Coagulopathy or anticoagulant therapy affecting platelet function
  • Neuropathy affecting pain perception
  • Known cardiac condition contraindicating treatment
  • Poorly controlled diabetes (HbA1c >9.0)
  • Pregnancy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
假比较器:Arm 1 - Control Exercise Therapy + Sham PRP + Sham Shockwave

A sham PRP injection will be performed where the needle breaks the skin but does not fenestrate the tendon. The sham ESWT will include radial pressure waves and focused shockwaves delivered without the device turned on to deliver energy and audio recording. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study.

A needle will be inserted but no injection will occur around the Achilles tendon

Both focused shockwave and radial pressure wave will be in contact with the skin, but the devices will not be active to deliver energy. An audio recording will provide noises similar to the machines operating.

实验性的:Arm 2 - Exercise Therapy + Platelet-Rich Plasma (PRP) + Sham Shockwave

PRP will be delivered around the tendon, sham ESWT will be issued. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study.

Both focused shockwave and radial pressure wave will be in contact with the skin, but the devices will not be active to deliver energy. An audio recording will provide noises similar to the machines operating.

Participants randomized to PRP will receive a single ultrasound-guided injection of approximately 3 mL of neutrophil-poor platelet-rich plasma derived from autologous blood. Blood will be processed to concentrate platelets and the PRP will be injected adjacent to the Achilles tendon at the site of maximal pain.

实验性的:Arm 3 - Exercise Therapy + Extracorporeal Shockwave Therapy (ESWT) + Sham PRP

Sham PRP will be delivered. Three sessions of ESWT will be delivered to the Achilles tendon. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study.

A needle will be inserted but no injection will occur around the Achilles tendon

Participants randomized to ESWT will receive three weekly treatment sessions. Focused shockwave therapy will deliver approximately 2000 shocks with gradual energy escalation, followed by radial shockwave therapy delivering approximately 3000 pulses to the Achilles tendon and 3000 pulses to surrounding musculature.

实验性的:Arm 4 - Exercise Therapy + Platelet-Rich Plasma + Extracorporeal Shockwave Therapy

PRP will be administered followed by three sessions of ESWT. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study.

Participants randomized to PRP will receive a single ultrasound-guided injection of approximately 3 mL of neutrophil-poor platelet-rich plasma derived from autologous blood. Blood will be processed to concentrate platelets and the PRP will be injected adjacent to the Achilles tendon at the site of maximal pain.

Participants randomized to ESWT will receive three weekly treatment sessions. Focused shockwave therapy will deliver approximately 2000 shocks with gradual energy escalation, followed by radial shockwave therapy delivering approximately 3000 pulses to the Achilles tendon and 3000 pulses to surrounding musculature.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Victorian Institute of Sport Assessment-Achilles (VISA-A)
大体时间:baseline, 8 weeks, 4 months, 6 months

The VISA-A is an eight item questionnaire measures Achilles tendon pain and function, with scores ranging from 0 to 100 (higher scores indicating better function).

baseline, 8 weeks, 4 months, 6 months

次要结果测量

结果测量
措施说明
大体时间
PROMIS-29 Patient Reported Outcomes
大体时间:Baseline, 8 weeks, 4 months, 6 months

Change in PROMIS-29 domain scores evaluating physical function, pain interference, fatigue, sleep disturbance, anxiety, depression, and social participation.

Baseline, 8 weeks, 4 months, 6 months
University of Wisconsin Running Injury and Recovery Index (UWRI)
大体时间:baseline, 8 weeks, 4 months, 6 months

Running-specific recovery and functional ability measure for participants who run regularly.

baseline, 8 weeks, 4 months, 6 months
Ultrasound Tendon Cross-Sectional Area
大体时间:baseline, 6 months

Changes in Achilles tendon cross-sectional area measured by ultrasound at the site of maximal tendon thickness.

baseline, 6 months
Heel Rise Test Endurance
大体时间:baseline, 6 months

Total number of single-leg heel raises performed until fatigue or inability to maintain pace or same height.

baseline, 6 months
Hop Test Pain
大体时间:baseline, 6 months

Pain rating following completion of a standardized single-leg hop test of 20 repetitions.

baseline, 6 months
Gait Biomechanics
大体时间:baseline, 6 months

Changes in lower extremity biomechanics and symmetry during walking and running assessed using motion capture and instrumented treadmill analysis in those who elect to complete biomechanical assessment.

baseline, 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Adam S. Tenforde, MD、Spaulding Rehabiltaition Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月15日

初级完成 (估计的)

2028年3月15日

研究完成 (估计的)

2028年9月30日

研究注册日期

首次提交

2026年3月15日

首先提交符合 QC 标准的

2026年3月15日

首次发布 (实际的)

2026年3月19日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月23日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

No identifiable information will be shared outside Mass General Brigham. We will consider publishing a limited deidentified data set at time of publication of our findings.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅